Platinum nanoplatforms: classic catalysts claiming a prominent role in cancer therapy.
Journal
Chemical Society reviews
ISSN: 1460-4744
Titre abrégé: Chem Soc Rev
Pays: England
ID NLM: 0335405
Informations de publication
Date de publication:
30 Aug 2022
30 Aug 2022
Historique:
pubmed:
20
8
2022
medline:
2
9
2022
entrez:
19
8
2022
Statut:
epublish
Résumé
Platinum nanoparticles (Pt NPs) have a well-established role as a classic heterogeneous catalyst. Also, Pt has traditionally been employed as a component of organometallic drug formulations for chemotherapy. However, a new role in cancer therapy is emerging thanks to its outstanding catalytic properties, enabling novel approaches that are surveyed in this review. Herein, we critically discuss results already obtained and attempt to ascertain future perspectives for Pt NPs as catalysts able to modify key processes taking place in the tumour microenvironment (TME). In addition, we explore relevant parameters affecting the cytotoxicity, biodistribution and clearance of Pt nanosystems. We also analyze pros and cons in terms of biocompatibility and potential synergies that emerge from combining the catalytic capabilities of Pt with other agents such as co-catalysts, external energy sources (near-infrared light, X-ray, electric currents) and conventional therapies.
Substances chimiques
Platinum
49DFR088MY
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM